ConductScience.org, home

Paper41127013

Case Report: Failed response to anti-PD-1 immunotherapy in a colon cancer patient with high microsatellite instability.

Li R and 7 others. Front Oncol, 2025. Cited by 2 papers, by iCite.

Cite this record

ConductScience Library. Case Report: Failed response to anti-PD-1 immunotherapy in a colon cancer patient with high microsatellite instability. Papers, record 41127013. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41127013

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Case Report: Failed response to anti-PD-1 immunotherapy in a colon cancer patient with high microsatellite instability.
PubMed
Journal
Front Oncol
PubMed
Year
2025
PubMed
Publication types
Case Reports, Journal Article
PubMed
Citations, by iCite
2
iCite
Revised in PubMed
2025-10-25
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Li RRong
2Lin YPYan-Ping
3Shen XXin
4Guo JYJiang-Yan
5Zhang YYa
6Tang JDJia-Dai
7Xie LLin
8Hu FDFeng-Di

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References36

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
133926917A Low Tumor Mutational Burden and PTEN Mutations Are Predictors of a Negative Response to PD-1 Blockade in MSI-H/dMMR Gastrointestinal Tumors.Clin Cancer Res2021https://conductscience.org/library/papers/33926917PubMed
233264544Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.N Engl J Med2020https://conductscience.org/library/papers/33264544PubMed
335506567NTRK fusion positive colorectal cancer is a unique subset of CRC with high TMB and microsatellite instability.Cancer Med2022https://conductscience.org/library/papers/35506567PubMed
435977594Pan-tropomyosin receptor kinase immunohistochemistry is a feasible routine screening strategy for NTRK fusions in mismatch repair-deficient colorectal carcinomas.Hum Pathol2022https://conductscience.org/library/papers/35977594PubMed
522933939Microsatellite instability in colorectal cancer.Radiol Oncol2011https://conductscience.org/library/papers/22933939PubMed
635680043Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study.Ann Oncol2022https://conductscience.org/library/papers/35680043PubMed
737142372Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study.Lancet Oncol2023https://conductscience.org/library/papers/37142372PubMed
830925919Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment.Mol Cancer2019https://conductscience.org/library/papers/30925919PubMed
935131862Inhibition of integrin αvβ6 sparks T-cell antitumor response and enhances immune checkpoint blockade therapy in colorectal cancer.J Immunother Cancer2022https://conductscience.org/library/papers/35131862PubMed
1039874977Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial.Lancet2025https://conductscience.org/library/papers/39874977PubMed
1132343640Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603).J Clin Oncol2020https://conductscience.org/library/papers/32343640PubMed
1239035212Cancer incidence and mortality in China, 2016.J Natl Cancer Cent2022https://conductscience.org/library/papers/39035212PubMed
1330742119Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma.Nat Med2019https://conductscience.org/library/papers/30742119PubMed
1434986285Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.N Engl J Med2022https://conductscience.org/library/papers/34986285PubMed
1537894457Unraveling Resistance to Immunotherapy in MSI-High Colorectal Cancer.Cancers (Basel)2023https://conductscience.org/library/papers/37894457PubMed
1639629124BATF2 inhibits the stem cell-like properties and chemoresistance of gastric cancer cells through PTEN/AKT/β-catenin pathway.Theranostics2024https://conductscience.org/library/papers/39629124PubMed
1736700211Genomic and transcriptomic analysis of MSI-H colorectal cancer patients with targetable alterations identifies clinical implications for immunotherapy.Front Immunol2022https://conductscience.org/library/papers/36700211PubMed
1835896284Overcoming resistance to αPD-1 of MMR-deficient tumors with high tumor-induced neutrophils levels by combination of αCTLA-4 and αPD-1 blockers.J Immunother Cancer2022https://conductscience.org/library/papers/35896284PubMed
1929891791TGF-β in T Cell Biology: Implications for Cancer Immunotherapy.Cancers (Basel)2018https://conductscience.org/library/papers/29891791PubMed
2031611702Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups.Nat Immunol2019https://conductscience.org/library/papers/31611702PubMed

See all 36 referencesDownload CSV of references

Cited by2

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.

PMIDTitleJournalYearIn PapersSource
42164656Regulation of Immune Checkpoints: From Molecular Mechanisms to Clinical Therapies.MedComm (2020)2026https://conductscience.org/library/papers/42164656PubMed
41601689Terminally exhausted CD8+ T cells in solid tumors: biology, biomarker potential and translational tools for precision oncology.Front Immunol2025https://conductscience.org/library/papers/41601689PubMed

Download CSV of cited by

Genes2

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
HLA-A3105PubTator's text mininghttps://conductscience.org/library/genes/3105NCBI Gene
PDCD15133PubTator's text mininghttps://conductscience.org/library/genes/5133NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41127013

GET https://conductscience.org/api/papers/v1/41127013/references?page=2